Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ANL
ANL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ANL News
Adlai Nortye Doses First Patient in AN9025 Clinical Trial
3d ago
Newsfilter
Adlai Nortye Secures $140M Private Placement Financing
Feb 03 2026
seekingalpha
Xpeng Inc Reports Disappointing Delivery Numbers, Stock Drops
Feb 02 2026
Benzinga
SanDisk Reports Strong Q2 Results, Shares Surge
Jan 30 2026
Benzinga
Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%
Jan 02 2026
Benzinga
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
Dec 30 2025
Benzinga
Xeriant Launches Factor X R&D Group Targeting $1.8 Trillion Green Construction Market
Dec 29 2025
Newsfilter
NASDAQ 100 Falls 126.91 Points; Active Pre-Market Trading Observed
Dec 29 2025
NASDAQ.COM
Adlai Nortye Enters Exclusive Licensing Agreement with ASK Pharma, Potential Revenue Up to RMB 1.6 Billion
Dec 29 2025
NASDAQ.COM
Adlai Nortye Secures RMB 1.6 Billion Exclusive Licensing Deal with ASK Pharm
Dec 29 2025
Globenewswire
Adlai Nortye Enters Exclusive Licensing Agreement with ASK Pharm for AN9025 Worth Up to $230 Million
Dec 29 2025
Newsfilter
Adlai Nortye Set to Attend Upcoming Investor Conferences
Nov 21 2025
Newsfilter
Adlai Nortye to Discuss AN4035 Preclinical Findings at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Treatments
Oct 22 2025
Newsfilter
HC Wainwright & Co. Downgrades Adlai Nortye to Neutral
Jun 02 2025
Benzinga
Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
Apr 10 2025
Newsfilter
Adlai Nortye Announces CFO Transition with Interim Appointment
Dec 31 2024
Business Insider
Show More News
